Search website

If you cannot find, what you are looking for, try searching for it below or visit our FAQ-page.

Close

2019.03.14

Tillotts Pharma AG and LabGenius Enter Development Agreement in Inflammatory Bowel Diseases

RHEINFELDEN, Switzerland, 14 March 2019 – Tillotts Pharma AG (“Tillotts”), part of the Japanese Zeria Group, and LabGenius announced today that they have entered into a discovery agreement to identify and develop new drug candidates for the treatment of inflammatory bowel diseases (IBD). IBD, such as ulcerative colitis (UC) and Crohn’s disease (CD), is a group of conditions where the body’s own immune system attacks parts of the gastrointestinal tract. Immune response regulation has a crucial role in controlling the intestinal inflammation and the symptoms of IBD as demonstrated by the clinical efficacy of anti-TNF therapies, the first biologics approved for UC and CD. However, there is still a large unmet need for novel therapeutic approaches in IBD, as many patients do not respond to the presently available drugs.

“Our agreement with LabGenius underscores our commitment to develop innovative therapies for the millions of patients suffering from IBD” said Thomas A. Tóth von Kiskér, CEO at Tillotts Pharma AG. “Moreover, it supports our strategy to strengthen our portfolio and R&D pipeline. We are doing this by further expanding into biotechnology and adding new developmet projects to TP10, our most advanced biologic program for IBD and other inflammations.”

Under the terms of the agreement, LabGenius will work over the course of the next two years towards the discovery of novel drugs using its artificial intelligence (AI) driven evolution engine for the discovery of high-value proteins. LabGenius will generate molecules and, together with Tillotts, will identify the lead candidates for future development and commercialisation by Tillotts.

”We are excited to apply our AI-driven technology to the development of novel drug candidates for IBD and support Tillotts in the development of new products that could potentially bring benefits to patients in need,” said James Field, CEO & Founder of LabGenius.

Read the full announcement in German here.

For more information, contact:

Tillotts Pharma AG

Federica Ricatto, Senior Communications Manager, Medical Affairs

Phone: +41 61 935 2749
Email: Federica.Ricatto@tillotts.com

LabGenius

James Field, CEO & Founder

Phone: +44 20 3627 7156
Email: hi@labgeni.us

About Tillotts

Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma company with more than 300 employees in Switzerland and abroad. Tillotts is engaged in advancing care and is committed to making a difference for the millions of people worldwide who suffer from GI-diseases.

All trademarks used or mentioned here are protected by law. © Copyright Tillotts Pharma AG. All rights reserved.

About Zeria

Zeria Pharmaceutical Co., Ltd., founded in 1955, based in Tokyo, Japan, operates internationally through a number of subsidiaries in the Ethical Pharmaceuticals and Consumer Healthcare businesses. Zeria is dedicated to research and development of pharmaceutical products and is specialised in the gastroenterology field, among others. The company is listed on the First Section of Tokyo Stock Exchange (Stock code: 4559).

About LabGenius

LabGenius Ltd. founded in 2012, based in London, UK, is a leading AI-driven protein engineering company. LabGenius deploys its discovery engine (EVA), in partnership with international companies, to solve demanding therapeutic challenges in the pharmaceutical sector. LabGenius is run by a multidisciplinary team of data scientists, synthetic biologists and engineers. For more information, please visit www.labgeni.us 


References

  • Guan Q. et al. Recent Advances: The Imbalance of Cytokines in the Pathogenesis of Inflammatory Bowel Disease. Mediators Inflamm. 2017; 2017:4810258.
  • Neurath M.F. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014; 14(5):329-42.
  • Neurath M.F. Current and emerging therapeutic targets for IBD. Nat Rev Gastroenterol Hepatol. 2017; 14(5):269-78.